HABA Laboratories,Inc. (TYO:4925)
Japan · Delayed Price · Currency is JPY 1,717.00
-4.00 (-0.23%)
Aug 21, 2026, 3:30 PM JST
HABA Laboratories,Inc. Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 12,038 | 12,141 | 12,061 | 12,324 | 12,038 | 12,908 | |
Revenue Growth | 0.16% | 0.66% | -2.13% | 2.38% | -6.74% | -9.78% |
Cost of Revenue | 4,063 | 4,054 | 3,969 | 3,920 | 3,869 | 4,114 |
Gross Profit | 7,975 | 8,087 | 8,092 | 8,404 | 8,169 | 8,794 |
Selling, General & Admin | 7,236 | 7,243 | 7,405 | 8,214 | 8,427 | 8,650 |
Operating Expenses | 7,367 | 7,374 | 7,503 | 8,591 | 8,778 | 9,111 |
Operating Income | 608 | 713 | 589 | -187 | -609 | -317 |
Interest Expense | -15 | -16 | -17 | -9 | -6 | -7 |
Interest & Investment Income | 2 | 2 | - | - | - | - |
Other Non Operating Income (Expenses) | 9 | 8 | 36 | 4 | 33 | 31 |
EBT Excluding Unusual Items | 604 | 707 | 608 | -192 | -582 | -293 |
Gain (Loss) on Sale of Investments | - | - | 7 | - | 6 | - |
Gain (Loss) on Sale of Assets | 141 | 141 | - | -3 | 9 | 1 |
Asset Writedown | - | - | - | -1,647 | -3 | -54 |
Other Unusual Items | 1 | 1 | 20 | -1 | 22 | 79 |
Pretax Income | 746 | 849 | 635 | -1,843 | -548 | -267 |
Income Tax Expense | 65 | 89 | 59 | 275 | 159 | 2 |
Net Income | 681 | 760 | 576 | -2,118 | -707 | -269 |
Net Income to Common | 681 | 760 | 576 | -2,118 | -707 | -269 |
Net Income Growth | 6.57% | 31.94% | - | - | - | - |
Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 | 4 |
Shares Change | -0.00% | -0.00% | - | - | -0.00% | -0.00% |
EPS (Basic) | 180.09 | 200.98 | 152.32 | -560.09 | -186.96 | -71.13 |
EPS (Diluted) | 180.09 | 200.98 | 152.32 | -560.09 | -186.96 | -71.13 |
EPS Growth | 6.57% | 31.95% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 1,160 | 1,483 | -741 | -136 | 1,590 |
Free Cash Flow Per Share | - | 306.76 | 392.17 | -195.95 | -35.96 | 420.46 |
Dividend Per Share | 40.000 | 40.000 | 40.000 | 40.000 | 40.000 | 40.000 |
Dividend Growth | 0% | 0% | 0% | 0% | 0% | 0% |
Gross Margin | 66.25% | 66.61% | 67.09% | 68.19% | 67.86% | 68.13% |
Operating Margin | 5.05% | 5.87% | 4.88% | -1.52% | -5.06% | -2.46% |
Profit Margin | 5.66% | 6.26% | 4.78% | -17.19% | -5.87% | -2.08% |
Free Cash Flow Margin | - | 9.55% | 12.30% | -6.01% | -1.13% | 12.32% |
EBITDA | 801 | 899 | 747 | 332 | -50 | 391 |
EBITDA Margin | 6.65% | 7.41% | 6.19% | 2.69% | -0.41% | 3.03% |
D&A For EBITDA | 193 | 186 | 158 | 519 | 559 | 708 |
EBIT | 608 | 713 | 589 | -187 | -609 | -317 |
EBIT Margin | 5.05% | 5.87% | 4.88% | -1.52% | -5.06% | -2.46% |
Effective Tax Rate | 8.71% | 10.48% | 9.29% | - | - | - |
Advertising Expenses | - | 2,550 | 2,629 | 3,027 | 3,104 | 3,323 |